Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Aurora, Colorado 80045


Purpose:

hypothesis: changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.


Study summary:

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be record at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.


Criteria:

Inclusion Criteria: - on Xalatan monotherapy from 1 t 18 months - 18 years of age or older - has been diagnosed with ocular surface disease Exclusion Criteria: - special populations such as children, pregnant females, prisoners, etc.


NCT ID:

NCT00554411


Primary Contact:

Principal Investigator
Malik Y Kahook, M.D.
Rocky mountain Lions Eye Institute


Backup Contact:

N/A


Location Contact:

Aurora, Colorado 80045
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 16, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.